Search Results
Dr. Kris on the Impact of Bevacizumab Biosimilars in Lung Cancer
Use of Bevacizumab for Lung Cancer
Dr. Kris on Search for Biomarkers in Advanced Squamous NSCLC
Use of Bevacizumab in Stage IV NSCLC With No Actionable Mutations
Dr. Cristofanilli on the Need for Biosimilars in Oncology
Dr. Hamilton on the Impact of Biosimilars in Oncology
BELIEF: Phase 2 trial of erlotinib plus bevacizumab for non-small cell lung cancer
ECOG 1505 Study: No Benefit of Post-Operative Avastin in Early Stage Lung Cancer Patients
Avastin not as beneficial to older lung cancer patients | Dana-Farber Cancer Institute
Dr. Schwartzberg on the Use of Therapeutic Biosimilars in Breast Cancer
Dr. Lyman on the Process for Approving Biosimilars
Bevacizumab in NSCLC
